Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features

被引：52

作者：

Wang, S. A. ^{[1
]}

Hasserjian, R. P.

Loew, J. M.

Sechman, E. V.

Jones, D.

Hao, S.

Liu, Q.

Zhao, W.

Mehdi, M.

Galili, N.

Woda, B.

Raza, A.

机构：

[1] Univ Massachusetts, Med Ctr, Dept Pathol, Amherst, MA 01003 USA

[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Cambridge, MA 02138 USA

[3] Rush Univ, Sch Med, Dept Pathol, Chicago, IL 60612 USA

[4] Univ Massachusetts, Med Ctr, Dept Med, Amherst, MA 01003 USA

[5] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[6] Univ Massachusetts, Med Ctr, Dept Canc Biol, Amherst, MA 01003 USA

来源：

LEUKEMIA | 2006年 / 20卷 / 09期

关键词：

D O I：

10.1038/sj.leu.2404316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1641 / 1644

页数：4

共 8 条

[1] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[2] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia [J].

Jelinek, J ;

Oki, Y ;

Gharibyan, V ;

Bueso-Ramos, C ;

Prchal, JT ;

Verstovsek, S ;

Beran, M ;

Estey, E ;

Kantarjian, HM ;

Issa, JPJ .

BLOOD, 2005, 106 (10) :3370-3373

[3] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[4]

*MASS GEN HOSP, 1992, NEW ENGL J MED, V326, P1137

[5] The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients [J].

Ohyashiki, K ;

Aota, Y ;

Akahane, D ;

Gotoh, A ;

Miyazawa, K ;

Kimura, Y ;

Ohyashiki, JH .

LEUKEMIA, 2005, 19 (12) :2359-2360

[6]

Schmitt-Graeff A, 2002, HAEMATOLOGICA, V87, P392

[7] Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults [J].

Shaw, GR .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :180-184

[8] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes [J].

Steensma, DP ;

Dewald, GW ;

Lasho, TL ;

Powell, HL ;

McClure, RF ;

Levine, RL ;

Gilliland, DG ;

Tefferi, A .

BLOOD, 2005, 106 (04) :1207-1209

← 1 →